Xopenex inhalation solution indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children six years of age and older with reversible obstructive airway disease, has been launched as part of an agreement with Sunovion Pharmaceuticals.
According to IMS Health data, Xopenex had total US sales of approximately $474m, for the most recent twelve months ending 30June 2012.
Watson Pharmaceuticals is an integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women’s Health.